GeneCradle Inc: Clinical Trials

6 trials sponsored by GeneCradle Inc, newest first
ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 2 active not recruiting, 1 not yet recruiting. 6 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Recruiting 3, Active not recruiting 2, Not yet recruiting 1
Phase 26Recruiting 3, Active not recruiting 2, Not yet recruiting 1

Follow GeneCradle Inc: new trials by email

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD)
GC310 - Wilson Disease		Phase 1 / Phase 2Not yet recruitingGeneCradle Inc152025-10-012025-09-15
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
GC101 - Spinal Muscular Atrophy Type 3		Phase 1 / Phase 2RecruitingGeneCradle Inc212024-05-102025-07-03
Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug
GC301 - Pompe Disease (Late-onset)		Phase 1 / Phase 2RecruitingGeneCradle Inc332024-04-192025-07-03
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients
GC101 - SMA II		Phase 1 / Phase 2Active not recruitingGeneCradle Inc332023-08-012025-07-03
Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy Drug
GC301 - Pompe Disease Infantile-Onset		Phase 1 / Phase 2Active not recruitingGeneCradle Inc162023-06-022025-07-03
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
GC101 - Spinal Muscular Atrophy		Phase 1 / Phase 2RecruitingGeneCradle Inc182023-02-252025-07-03

Conditions studied

Spinal Muscular Atrophies of Childhood (2)  ·  Glycogen Storage Disease Type II (1)  ·  Hepatolenticular Degeneration (1)  ·  Muscular Atrophy, Spinal (1)

Countries

China (6)

Top investigators

Guang Yang (1)